New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Boston, MA -- (SBWire) -- 06/04/2014 --Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014', provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

View Full Report Details and Table of Contents

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects

Companies Mentioned in this Report: Johnson & Johnson, Boehringer Ingelheim GmbH, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Bavarian Nordic A/S, Isis Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Oxford BioMedica plc, Plexxikon Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Aphios Corporation, Astellas Pharma Inc., Orion Corp, Astex Pharmaceuticals, Inc., Santaris Pharma A/S, A. Menarini Industrie Farmaceutiche Riunite Srl, Bayer AG, Harbor Therapeutics, Inc., Celldex Therapeutics, Inc., ValiRx Plc, AEterna Zentaris Inc., Arrowhead Research Corporation, Northwest Biotherapeutics, Inc., Medivation, Inc., Oncogenex Pharmaceuticals, Inc., AnGes MG, Inc., e-Therapeutics plc, Hybrigenics S.A., Fujifilm Corporation, CureVac GmbH, Tokai Pharmaceuticals, Inc., Arno Therapeutics, Inc., Orphagen Pharmaceuticals, Inc., Enceladus Pharmaceuticals BV, NewLink Genetics Corporation, Kinex Pharmaceuticals, LLC, Adamis Pharmaceuticals Corporation, CureTech Ltd., Viamet Pharmaceuticals, Inc., Incuron, LLC, Ausio Pharmaceuticals, LLC, Errant Gene Therapeutics, LLC, Miami VA Healthcare System, Tesaro, Inc., Panacela Labs, Inc., Io Therapeutics, Inc., Antoxis Limited, Armour Therapeutics Inc., Medvio Eurasia, Biscayne Pharmaceuticals, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
- Metastatic Prostate Cancer - Pipeline Review, H1 2014
- Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Breast Cancer - Pipeline Review, H1 2014
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014